Foley Hoag advised H.I.G. BioHealth Partners and Accelmed Partners on the deal. H.I.G. BioHealth Partners and Accelmed Partners acted as new investors and co-leads in the...
You must be a Standard 1 Year member to access this content.
Foley Hoag advised Alcyone Therapeutics on the deal. Alcyone Therapeutics, a Lowell, Massachusetts-based biotechnology company pioneering next-generation precision central nervous system (CNS) therapies, closed $23 million in...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP advised The Valens Company Inc. on the deal. The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF), a leading manufacturer of cannabis products, announced a...
You must be a Standard 1 Year member to access this content.
